Spots Global Cancer Trial Database for homologous recombination deficiency
Every month we try and update this database with for homologous recombination deficiency cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer | NCT04651920 | Epithelial Ovar... Chinese Homologous Reco... BRCA1 Mutation BRCA2 Mutation Prognosis Homologous Reco... | Evaluation of h... | 18 Years - | Peking Union Medical College Hospital | |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | NCT04503265 | Advanced Malign... Breast Cancer Ovarian Cancer Homologous Reco... Prostate Cancer Pancreatic Canc... | AMXI-5001:Dose ... AMXI-5001:Dose ... | 18 Years - | AtlasMedx, Incorporated | |
| Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | NCT06433219 | Ovarian Cancer | Tuvusertib (M17... Niraparib Lartesertib (M4... | 18 Years - | EMD Serono | |
| A Training Set for the HRD Model in EOC | NCT04651933 | Epithelial Ovar... BRCA Mutation Loss of Heteroz... Prognosis Platinum Resist... Homologous Reco... | Homologous reco... | 18 Years - | Peking Union Medical College Hospital | |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT05005728 | Metastatic Cast... | vudalimab + car... vudalimab + ola... vudalimab monot... vudalimab + doc... vudalimab + cab... | 18 Years - | Xencor, Inc. | |
| Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO | NCT05033756 | Malignant Neopl... Breast Cancer | Pembrolizumab I... Olaparib Oral T... | 18 Years - | Institut fuer Frauengesundheit | |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) | NCT01968213 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Rucaparib Placebo | 18 Years - | pharmaand GmbH | |
| AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer | NCT04499118 | HER2-negative B... | AT regimen TP regimen | 18 Years - | Sichuan Provincial People's Hospital | |
| Olaparib in Patients With HRD Malignant Mesothelioma | NCT04515836 | Mesothelioma Homologous Reco... | Olaparib | 18 Years - | University of Chicago | |
| Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | NCT04240106 | Breast Cancer Breast Cancer M... | Niraparib Aromatase Inhib... | 18 Years - | MedSIR | |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | NCT03442556 | ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Castration Leve... Castration-Resi... Homologous Reco... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... | Carboplatin Docetaxel Laboratory Biom... Rucaparib Camsy... Rucaparib | 18 Years - | University of Washington | |
| Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors | NCT06177171 | BRCA1 Mutation BRCA2 Mutation BRCA Mutation PALB2 Gene Muta... Checkpoint Kina... ATM Gene Mutati... | Olaparib ASTX727 | 18 Years - | University of California, San Francisco | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer | NCT04499118 | HER2-negative B... | AT regimen TP regimen | 18 Years - | Sichuan Provincial People's Hospital | |
| HRD and Resistance to PAPPi in EOC Patients | NCT05310370 | Epithelial Ovar... Homologous Reco... Homologous Reco... Poly(ADP-ribose... Drug Resistance Progression-fre... Overall Surviva... | Testing of homo... | 18 Years - | Peking Union Medical College Hospital | |
| The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer | NCT06242392 | Ovarian Neoplas... | homologous reco... | 18 Years - | Fujian Cancer Hospital | |
| Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | NCT04240106 | Breast Cancer Breast Cancer M... | Niraparib Aromatase Inhib... | 18 Years - | MedSIR | |
| HRD and Resistance to PAPPi in EOC Patients | NCT05310370 | Epithelial Ovar... Homologous Reco... Homologous Reco... Poly(ADP-ribose... Drug Resistance Progression-fre... Overall Surviva... | Testing of homo... | 18 Years - | Peking Union Medical College Hospital | |
| Olaparib in Patients With HRD Malignant Mesothelioma | NCT04515836 | Mesothelioma Homologous Reco... | Olaparib | 18 Years - | University of Chicago | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies | NCT03209401 | Solid Tumor, Ad... Homologous Reco... | Niraparib Carboplatin | 18 Years - | Georgetown University | |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | NCT01482715 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Advanced Solid ... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer With Homologous Recombination Deficiency That Has Spread to the Liver | NCT05182112 | Pancreatic Canc... | Whole liver irr... Gemcitabine and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | NCT03432676 | ATM Gene Mutati... Deleterious BRC... Deleterious BRC... Homologous Reco... Pancreatic Duct... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... | Epacadostat Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Functional Analysis of BRCAness | NCT04780945 | Ovarian Neoplas... Homologous Reco... BRCA1 Mutation BRCA2 Mutation | Functional RAD5... Olaparib Oral P... | 18 Years - | Leiden University Medical Center | |
| A Training Set for the HRD Model in EOC | NCT04651933 | Epithelial Ovar... BRCA Mutation Loss of Heteroz... Prognosis Platinum Resist... Homologous Reco... | Homologous reco... | 18 Years - | Peking Union Medical College Hospital | |
| Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency | NCT05461690 | Homologous Reco... Triple Negative... | Niraparib | 18 Years - | Zhejiang Cancer Hospital | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD | NCT00448266 | Breast Cancer | Intensified Cyc... dose dense adri... | 18 Years - 59 Years | The Netherlands Cancer Institute | |
| Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer | NCT04190667 | Epithelial Ovar... Chinese Homologous Reco... BRCA1 Mutation BRCA2 Mutation Prognosis | Genomic testing | 18 Years - | Peking Union Medical College Hospital | |
| A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer | NCT05775549 | Advanced Ovaria... | None (Observati... | 18 Years - 130 Years | AstraZeneca | |
| Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies | NCT03209401 | Solid Tumor, Ad... Homologous Reco... | Niraparib Carboplatin | 18 Years - | Georgetown University | |
| A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer | NCT05775549 | Advanced Ovaria... | None (Observati... | 18 Years - 130 Years | AstraZeneca | |
| Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer | NCT05466786 | Breast Cancer HER2-low Breast... | Standard Manage... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT05005728 | Metastatic Cast... | vudalimab + car... vudalimab + ola... vudalimab monot... vudalimab + doc... vudalimab + cab... | 18 Years - | Xencor, Inc. | |
| Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer | NCT05466786 | Breast Cancer HER2-low Breast... | Standard Manage... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies | NCT03209401 | Solid Tumor, Ad... Homologous Reco... | Niraparib Carboplatin | 18 Years - | Georgetown University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
